46
MEDYA
TR
EN
Home
Genel
News Detail
Morning Star
June 1, 2026
|
01:01
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
...
Full Story at Source
Related News
'I have no preexisting conditions': I'm 56, earn $198,000 and want to retire early. Can I afford private healthcare?
Oil rises, U.S. stock futures flat as Wall Street looks to extend its winning streak
Trump seeking edits to US-Iran deal, US media report
Dell unveils $699 XPS 13 laptop in challenge to Apple's MacBook Neo
